PDIA4 and metabolic disease: Previous clinical studies have found that the serum expression of PDIA4 from patients with metabolic disease is significantly higher than that of patients without metabolic disease, suggesting that PDIA4 has the potential as a new therapeutic target for metabolic disease or IR (17).